CA-125 Antigen

"CA-125 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A carbohydrate antigen that occurs in tumors of the ovary as well as in breast, kidney, and gastrointestinal tract tumors and normal tissue. While it is tumor-associated, it is not tumor-specific and may have a protective function against particles and infectious agents at mucosal surfaces.

Descriptor ID	D018394
MeSH Number(s)	D12.776.395.560.631.050 D23.050.285.050.225 D23.050.550.325.225 D23.101.140.075.225
Concept/Terms	CA-125 Antigen CA-125 Antigen Antigen, CA-125 Antigen CA-125 Antigen CA 125 Mucin-16 Mucin 16 CA 125 Antigen Antigen, CA 125

Below are MeSH descriptors whose meaning is more general than "CA-125 Antigen".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Glycoproteins [D12.776.395]
Mucoproteins [D12.776.395.560]
Mucins [D12.776.395.560.631]
CA-125 Antigen [D12.776.395.560.631.050]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Neoplasm [D23.050.285]
Antigens, Tumor-Associated, Carbohydrate [D23.050.285.050]
CA-125 Antigen [D23.050.285.050.225]
Epitopes [D23.050.550]
Antigens, Tumor-Associated, Carbohydrate [D23.050.550.325]
CA-125 Antigen [D23.050.550.325.225]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]
Antigens, Tumor-Associated, Carbohydrate [D23.101.140.075]
CA-125 Antigen [D23.101.140.075.225]

Below are MeSH descriptors whose meaning is related to "CA-125 Antigen".

Below are MeSH descriptors whose meaning is more specific than "CA-125 Antigen".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "CA-125 Antigen" by people in this website by year, and whether "CA-125 Antigen" was a major or minor topic of these publications.

Bar chart showing 9 publications over 7 distinct years, with a maximum of 2 publications in 2002 and 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	2	2
2010	1	0	1
2011	1	1	2
2014	0	1	1
2015	1	0	1
2018	1	0	1
2021	0	1	1

Below are the most recent publications written about "CA-125 Antigen" by people in Profiles.

Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.

View in: PubMed
Singha B, Harper SL, Goldman AR, Bitler BG, Aird KM, Borowsky ME, Cadungog MG, Liu Q, Zhang R, Jean S, Drapkin R, Speicher DW. CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. Sci Rep. 2018 10 03; 8(1):14725.

View in: PubMed
Berger Y, Nevler A, Shwaartz C, Lahat E, Zmora O, Gutman M, Shabtai M. Elevations of serum CA-125 predict severity of acute appendicitis in males. ANZ J Surg. 2016 Apr; 86(4):260-3.

View in: PubMed
Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer. 2014 Nov 01; 120(21):3311-9.

View in: PubMed
Skaznik-Wikiel ME, Sukumvanich P, Beriwal S, Zorn KK, Kelley JL, Richard SD, Krivak TC. Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report. Int J Gynecol Cancer. 2011 Aug; 21(6):1013-7.

View in: PubMed
Brody JR, Witkiewicz AK, Yeo CJ. The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer. Adv Surg. 2011; 45:301-21.

View in: PubMed
Richard SD, Sukumvanich P, Lesnock JL, McBee WC, Beriwal S, Edwards RP, Zorn KK, Krivak TC. Intraperitoneal catheter leads to prolongation of the time to normalization of serum CA125 levels. Int J Gynecol Cancer. 2010 Aug; 20(6):932-5.

View in: PubMed
Householder J, Han A, Edelson MI, Eager JM, Rosenblum NG. Immunohistochemical confirmation of pulmonary papillary adenocarcinoma metastatic to ovaries. Arch Pathol Lab Med. 2002 Sep; 126(9):1101-3.

View in: PubMed
Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 2002 Jul; 9(7):553-66.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement